H-Index
75
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
18%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

Get your full text copy in PDF

Cerebrospinal fluid tumor marker levels in predicting response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer.

Christos Kosmas, Nicolas B Tsavaris, George Tsakonas, Georgia Soukouli, Argyris Gassiamis, Nicolas Mylonakis, Athanasios Karabelis

Med Sci Monit 2005; 11(8): CR398-401

ID: 202098


Background: The aim of this study was to evaluate the predictive valueof cerebrospinal fluid (CSF) tumor marker levels in patients with breast cancer and carcinomatous meningitis.Material/Methods: Serial CSF and serum tumor marker (CEA, CA-15.3, CA-125, and CA-19.9) measurementswere performed in five patients with breast cancer developing carcinomatous meningitis in an attemptto correlate these with clinical outcome under treatment. Results: CSF tumor marker levels correlatedwith response to treatment and outcome in each patient; despite achieving negative CSF cytology aftertherapy, in two patients it heralded disease progression. Conclusions: Given our findings, CSF tumormarker evaluation may provide a reliable means and surrogate end-points of monitoring response of carcinomatousmeningitis to treatment. Therefore, large studies to assess the value of CSF tumor marker changes incarcinomatous meningitis are warranted.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree